Caballero A Enrique
Latino Diabetes Initiative, Joslin Diabetes Center, Harvard Medical School, One Joslin Place, Boston, MA 02215, USA.
Curr Diab Rep. 2004 Aug;4(4):237-46. doi: 10.1007/s11892-004-0074-9.
Subjects with obesity, family history of type 2 diabetes, polycystic ovary syndrome, previous gestational diabetes, dyslipidemia, hypertension, impaired glucose tolerance or impaired fasting glucose, and those with metabolic syndrome are at risk for the development of type 2 diabetes. Some of them are also at risk for cardiovascular disease. Some underlying abnormalities such as insulin resistance, endothelial dysfunction, and low-grade chronic inflammation are frequently present and closely associated in all these groups. The flow of substrates, hormones, and cytokines from visceral fat to skeletal muscle and to the endothelial cells, along with some genetic abnormalities that lead to impaired insulin action in the peripheral tissues and to impaired insulin-stimulated nitric oxide production in endothelial cells, may play a role in establishing these shared metabolic and vascular derangements. Weight loss, thiazolidinediones, and metformin improve vascular function in subjects at risk for type 2 diabetes and may prove to reduce cardiovascular events in these individuals.
患有肥胖症、2型糖尿病家族史、多囊卵巢综合征、既往妊娠糖尿病、血脂异常、高血压、糖耐量受损或空腹血糖受损的患者,以及患有代谢综合征的患者有患2型糖尿病的风险。其中一些人也有患心血管疾病的风险。在所有这些人群中,经常存在一些潜在异常,如胰岛素抵抗、内皮功能障碍和低度慢性炎症,且它们密切相关。从内脏脂肪到骨骼肌和内皮细胞的底物、激素和细胞因子的流动,以及一些导致外周组织胰岛素作用受损和内皮细胞胰岛素刺激的一氧化氮生成受损的基因异常,可能在建立这些共同的代谢和血管紊乱中起作用。减肥、噻唑烷二酮类药物和二甲双胍可改善有2型糖尿病风险患者的血管功能,并可能证明可减少这些个体的心血管事件。